Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Study Evaluating the Efficacy of Rituximab Plus Modified VPDL for Newly Diagnosed CD20-Positive Philadelphia-Negative Adult Acute Lymphoblastic Leukemia.

Next Previous
Search
Trial Profile

Phase 2 Study Evaluating the Efficacy of Rituximab Plus Modified VPDL for Newly Diagnosed CD20-Positive Philadelphia-Negative Adult Acute Lymphoblastic Leukemia.

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rituximab (Primary) ; Asparaginase; Asparaginase; Cytarabine; Daunorubicin; Etoposide; Folinic acid; Imatinib; Mercaptopurine; Methotrexate; Prednisolone; Vincristine
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Acronyms RADICAL

    • Most Recent Events

    • 22 Jul 2018 Planned End Date changed from 1 Oct 2017 to 1 Jan 2019.
    • 18 Jul 2017 Planned End Date changed from 1 Oct 2015 to 1 Oct 2017.
    • 18 Jul 2017 Planned primary completion date changed from 1 Oct 2015 to 1 Oct 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top